Stryker Co. (NYSE:SYK) Receives $420.68 Consensus PT from Brokerages

Stryker Co. (NYSE:SYK) has been assigned a consensus recommendation of “Moderate Buy” from the twenty ratings firms that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $420.68.

A number of research firms have issued reports on SYK. Barclays lifted their price target on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. The Goldman Sachs Group lifted their price target on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research note on Thursday, January 30th. Evercore ISI lifted their price target on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research note on Tuesday. Finally, Piper Sandler reiterated an “overweight” rating and set a $420.00 price target (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stryker

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Ascent Group LLC raised its holdings in Stryker by 5.6% during the 4th quarter. Ascent Group LLC now owns 4,083 shares of the medical technology company’s stock valued at $1,470,000 after acquiring an additional 216 shares during the period. Putney Financial Group LLC bought a new stake in Stryker during the 4th quarter valued at $292,000. Aurdan Capital Management LLC bought a new stake in Stryker during the 4th quarter valued at $312,000. Mackenzie Financial Corp raised its holdings in Stryker by 18.3% during the 4th quarter. Mackenzie Financial Corp now owns 1,416,994 shares of the medical technology company’s stock valued at $510,189,000 after acquiring an additional 219,451 shares during the period. Finally, Forum Financial Management LP raised its holdings in Stryker by 31.7% during the 4th quarter. Forum Financial Management LP now owns 2,455 shares of the medical technology company’s stock valued at $884,000 after acquiring an additional 591 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $382.59 on Monday. Stryker has a one year low of $314.93 and a one year high of $406.19. The firm has a market capitalization of $145.99 billion, a price-to-earnings ratio of 49.30, a PEG ratio of 2.93 and a beta of 0.96. The business has a 50-day simple moving average of $378.07 and a 200 day simple moving average of $368.67. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business posted $3.46 earnings per share. On average, research analysts anticipate that Stryker will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.